Next, in 2014, Su et al. demonstrated that multiple noninvasive biomarkers, including both genetic markers (mutations of TP53 249 T) and epigenetic markers (aberrant methylation of RASSF1A (mRASSF1A) and GSTP1 (mGSTP1) genes), were detected in in the urine of patients with HCC. Here, TP53 is linked to hepatocellular carcinoma.